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– detection of active ﬁbrogenesis in human lung
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Tashfeen Aslam,‡a Amy Miele,‡b Sunay V. Chankeshwara,‡a Alicia Megia-Fernandez,a
Chesney Michels,b Ahsan R. Akram,b Neil McDonald,b Nik Hirani,b Chris Haslett,b
Mark Bradley*a and Kevin Dhaliwal*b
Aberrant ﬁbrogenesis is a feature of many diseases in multiple organ systems. The lysyl oxidase family of
enzymes are central to tissue homeostasis and elevated lysyl oxidase activity is implicated in
ﬁbroproliferation as well as in cancer stroma. We have synthesised a novel ﬂuorogenic reporter for
monitoring lysyl oxidase activity that generates a 3–5 fold increase in ﬂuorescence following probe
activation in ventilating ﬁbrotic ex vivo asinine lung and ex vivo human lung tissue. The probe termed
“oLOX” can provide real-time measurement of lysyl oxidase activity in a number of biological settings
and is tractable from an in vitro setting to man.Introduction
Aberrant brogenesis is a feature of many diseases in multiple
organ systems and is characterised by tissue injury, remodelling
and incomplete repair resulting in the excessive deposition of
collagen.1,2 Fibrogenesis is a prominent feature of several lung
diseases ranging from adult respiratory distress syndrome in
intensive care to chronic obstructive pulmonary disease and
interstitial lung diseases.3 The global impact of these diseases is
huge, causing signicant nancial burden.4 Despite this,
treatment options are very limited and monitoring of disease
progression remains a challenge, as there are no rapid bedside
biomarkers that can detect active broproliferation. Blood
biomarkers oﬀer poor molecular specicity for lung pathology,
while pulmonary biopsy is invasive and xed tissue cannot
inform on the dynamic enzyme activity that exists in vivo.5
The Lysyl oxidases are copper dependent amine oxidases
that play a central role in brogenesis.6 They facilitate the
covalent cross-linking found within elastin and collagen by
catalysing the oxidative deamination of peptidyl-lysine and
hydroxylysine residues, a step that is crucial to the mature andof Edinburgh, Joseph Black Building, West
il: mark.bradley@ed.ac.uk
p, MRC/Centre of Inammation Research,
ty of Edinburgh, 47 Little France Crescent,
iwal@ed.ac.uk
ESI) available: Fig. S1, full experimental
f compounds 1–11. Detail information
tissue models, western blot,
uorescence microscopy (FCFM). See
Chemistry 2015functional extracellular matrix.7–9 There are ve proteins within
the lysyl oxidase family (LOXF): LOX, LOXL1 (lysyl oxidase like-
one), LOXL2, LOXL3 and LOXL4, all of which share the same
enzymatically active C-terminus and the cofactor lysine tyro-
sylquinone.10,11 A by-product of all of these enzymes is hydrogen
peroxide. Lysyl oxidases are important in cancer progression
and in many brotic diseases, including those aﬀecting the
lung.12–15 Of the 5 members of the LOXF, two in particular have
been the basis of extensive investigation and therapeutic tar-
geting: LOX and LOXL2. LOX expression correlates with poor
survival and is a therapeutic target for patients with certain
cancers,14 while LOXL2 is a focus in the monitoring and treat-
ment of brotic lung disease.15,16
As the potential for lysyl oxidases as therapeutic targets
becomes clear, there is a discernible need for the development
of selective and sensitive oxidase substrates to monitor enzy-
matic activity in complex biological systems. As a result, uo-
rescence-based analysis methods have attracted much attention
as they can provide simple, eﬀective and powerful tools17 for
real-time monitoring of LOX enzyme activities in vitro and in
vivo.18–20 Until recently, such reporters have been designed
either on a coumarin21,22 or resorun23 scaﬀold and are based on
a single amine oxidation/b-elimination resulting in an ampli-
cation of uorescent signal. However, the excitation wave-
length for coumarin (lex 360 nm) limits its applicability for
cellular-based imaging. Amplex red (N-acetyl-3,7-dihydrox-
yphenoxazine) is a non-uorescent derivative of dihydroresor-
un that is converted to uorescent resorun on reaction with
hydrogen peroxidase.24,25 This reagent has been utilised in a
number of settings including the quantication of neutrophil
NADPH oxidase, monoamine oxidase (MAO), glucose oxidase
and LOX.19,24,25 While providing a sensitive method for theChem. Sci.
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View Article Onlinedetection of hydrogen peroxide,26 Amplex red is non-specic
and clearly cannot be used in vivo or in cells.19
In a recent publication, Li et al. reported a probe for the
uorometric detection of monoamine oxidases A and B in vitro.
The probe was synthesised over 5 steps using the familiar and
inexpensive dye, uorescein 3. While utilising the amine
oxidation/b-elimination mechanism in the presence of MAO-A
and B, the uorescent reporter probe was methyl uorescein, a
dye with a lower quantum yield than 4.27 In order to develop a
probe for demonstrating the activity of LOXF in vivo, a reporter
probe with higher quantum yield was required. Herein, we
report the synthesis and ex vivo biological evaluation of an easily
synthesised activity-based uorescent probe for LOXF that
utilises a uorescein scaﬀold (Scheme 1).
To validate the activation of the optical LOXF probe (oLOX) 1
in the presence of LOX, selective inhibition was desired. b-
Aminopropionitrile (BAPN) has been extensively used as the
reference LOX inhibitor, with a reported IC50 of 10 mM.28
Though BAPN is widely used as a specic irreversible inhibitor
of LOX, it does have aﬃnity for other oxidases,29,30 indeed its
structure suggests non-specicity. Over the last two decades
selective inhibitors of LOX, as anti-brotic agents, have been
developed.31–35 Of these the pyridazinone-based class are amongScheme 1 (a) Pathway for the ﬂuorescence activation of probe oLOX 1 by
4 A˚ MS, 40 C, 48 h, 5 (15%) and 6 (65%); (ii) HCl, DCM/ether, 2 h, 93%.
Chem. Sci.the most potent (IC50 0.005–0.07 mM).36 Compounds 10 (IC50 3
nM)37 and 11 were thus synthesized for application in inhibition
studies (Scheme 2).
oLOX was evaluated for LOX activity in freshly isolated
human lung tissue, showing for the rst time, the ability to
measure the dynamic activity of LOXF with optical detection in
this model and the potential for in vivo utility.Results and discussion
Synthesis of optical LOXF probes
The chemical “masking” of the phenol groups of uorescein
can suppress uorescence and facilitate cell permeability.38,39 In
this investigation, both phenolic groups of 3 were selectively
alkylated with aminopropyl moieties, it being hypothesised that
upon treatment of oLOX 1 with the appropriate oxidases, the
two amino groups would be oxidised to give the bis-aldehyde 2
followed by dual b-elimination to release acrolein and uores-
cein 4 (Scheme 1a).
The synthesis of oLOX 1 was complicated due to the nature
of xanthene dyes such as uorescein, which exists in either of
the two forms, the quinoid 4 and/or lactone 3 form, depending
on the pH and solvent environment.40 The uorescent, xanthen-LOX. (b) Synthetic route for oLOX, (i) Br(CH2)3NHBoc, Ag2O, MeCN, py,
This journal is © The Royal Society of Chemistry 2015
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View Article Online3-one tautomer form, is favoured in non-acidic aqueous solu-
tions; whereas a non-uorescent, lactone tautomer 3, is fav-
oured at acidic pH's or in non-aqueous solvents. Typically
alkylation of uorescein gives the dual ether/ester (6) as the
major product, rather than the bis-ether (5). To develop the
optimal conditions to synthesise the desired bis-ether product
1, reactions conditions were optimised looking at various
solvents and bases.41 It is known that the use of heterogeneous
Ag(I) salts favours the desired phenol alkylation reaction over
ester formation, and the use of silver oxide in acetonitrile42 with
molecular sieves was eﬀective for the synthesis of 5 in moderate
yield (Scheme 1b), with the crude reaction mixture aﬀording 5
and 6 in 15% and 65% yields, respectively. 5 was non-uores-
cent while quinoid 6 showed emission characteristics (lmax ¼
520 nm) of uorescein. Treatment of 5 with hydrochloric acid in
DCM/ether gave reporter 1 as its HCl salt in quantitative yield.
As anticipated, the nal probe had good aqueous solubility and
was non-uorescent.
The two specic and potent LOX inhibitors 10 and 11 were
synthesised (Scheme 2). 11 was designed based on structure
activity relationship of similar inhibitors where the introduc-
tion of 4-(p-uorophenyl)phenol signicantly enhanced theFig. 1 LOX and LOXL2 are expressed in aged human lung tissue
homogenates. (a) Immunohistochemical analysis and (b) western blot
of LOX and LOXL2 expression in aged human (55–81 years) lung tissue.
Strongest bands for LOX were at 50 kDa, consistent with the glyco-
sylated pro-lysyl oxidase, but mature 32 kDa LOX was also present in
several samples (ESI, Fig. S1†). Data representative of a minimum of 3
experimental replicates. Scale-bar ¼ 100 mm.
Scheme 2 Synthetic route to the LOX inhibitors. (i) Mucochloric acid, 50%
70%; (iii) bisphenol derivative, CuI, Cs2CO3, BINOL, dioxane, reﬂux, 12 h,
This journal is © The Royal Society of Chemistry 2015potency of the inhibitor.32 2-Phenyl-3(2H)-pyridazinones, were
synthesised in two steps by condensation of mucochloric acid
with aryl hydrazine to aﬀord the dichloro pyrazone derivative 7.
In the next step, nucleophilic substitution with N-Boc pipera-
zine derivative aﬀorded 8. Reaction of 8 with 4-phenylphenol or
4-(p-uorophenyl)phenol and Boc deprotection aﬀorded the
inhibitors 10 and 11 in good yields (50–55%).
LOX and LOXL2 are expressed in human lung tissue
LOX is important in lung development and is expressed in
normal lung tissue.43,44 Pathological activity of LOXL2 has been
shown by Barry-Hamilton et al. with increased expression of
LOXL2 in the lung tissue of patients with idiopathic pulmonary
brosis (IPF),15 while Chien et al. found an association between
serum LOXL2 levels and the progression of IPF.16 Increased
expression of LOX has also been well demonstrated in experi-
mental models of pulmonary brosis.45,46 Hence we wished in
particular to begin evaluating our probe in the setting of human
lung pathology.
The expression of LOX and LOXL2 was rstly conrmed in
aged human (55–81 years) lung tissue homogenates using
western blot and immunohistochemistry. The 50 kDa pro-LOX
is secreted from cells then cleaved to the 32 kDa mature protein
by bone morphogenetic protein-1.10 In this study we demon-
strated the presence of the 50 kDa pro-LOX protein and the
active 32 kDa LOX protein in human lung tissue as well as the
enzymatically active 63 kDa LOXL2 (Fig. 1). Immunohisto-
chemical data supported previous ndings whereby LOX and
LOXL2 were found to be expressed in lung tissue.15 Since LOX
and LOXL2 were expressed in human lung tissue, homogenised
lung tissue was deemed an appropriate model to evaluate the
utility of the activity-based sensor oLOX 1 (Scheme 1).
oLOXF detects increased LOXF activity in aged human tissue
and is inhibited by selective inhibitors
Incubation of oLOX with lung tissue homogenate resulted in up
to a 300% increase in uorescence (Fig. 2a). The temporal
kinetics of oLOX activation with human tissue at the concen-
trations used in this study showed signicant uorescence
amplication aer 30 min (p < 0.01) and plateaued between 50
min and 2 h (ESI Fig. S2†). Importantly, oLOX activation wasaq. MeOH, 3 h, 60%; (ii)N-Boc-piperazine, NaI, dioxane, 100 C, 20 h,
58–73%; (iv) 20% TFA in DCM, 1 h, quantitative.
Chem. Sci.
Fig. 2 oLOX is activated in the presence of aged human lung tissue homogenate as shown by an inhibitable increase in ﬂuorescence. (a)
Fluorescent intensity of 10 mM oLOX after 2 h incubation with aged human lung tissue homogenate (solid line)  500 mM BAPN. Spectra were
recordedwith lex¼ 450 nm. (b–d) Human lung homogenate was pre-incubated with dilutions of inhibitors at 37 C for 1 h prior to the addition of
10 mM oLOX. Each graph shows the resultant ﬂuorescence presented as percentage above background after 1 h incubation of the reaction
(representative of n ¼ 3). The minimum concentration of BAPN (b) and Inh-1 (c) found to have a signiﬁcant inhibitory eﬀect was 62 mM (p < 0.01,
one way ANOVA), whereas the minimum concentration of Inh-2 (d) found to have a signiﬁcant inhibitory eﬀect was 15 mM (p < 0.01, one way
ANOVA). The dotted line represents background ﬂuorescence of oLOX, error bars depict standard deviation.
Fig. 3 oLOX is not activated by monoamine oxidases. Human lung
homogenate was pre-incubated (in triplicate) with 500 mM of BAPN,
clorgyline and/or pargyline at 37 C for 1 h prior to the addition of 10
mM oLOX. The bar show the mean resultant ﬂuorescence intensity
after 2 h incubations (n¼ 3). ***p < 0.001, one way ANOVA, dotted line
represents background ﬂuorescence of oLOX, error bars depict
standard error of the mean.
Chemical Science Edge Article
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View Article Onlinecompletely inhibited in a concentration dependent manner by
pre-incubation of the homogenate with BAPN (Fig. 2b) and the
inhibitors 10 and 11 (Fig. 2c and d). As predicted inhibitor 11
was a more potent inhibitor of probe activation (Fig. 2d). BAPN
is a time and temperature dependant47 irreversible inhibitor of
LOX.48,49 BAPN has been shown to inhibit LOXL1,50 LOXL3 51
and LOXL4,52 but inhibition of LOXL2 by BAPN is more
controversial with mixed reports of success.26,53 We have shown
that both active LOX and LOXL2 are present within the lung
tissue homogenates and hypothesise that each of these enzymes
contribute to the increase in uorescent signal observed with
our probe. We have not investigated the expression of other
members of the LOXF within the lung tissue and it is certainly
possible that they are present at low levels, contributing to the
uorescent signal.
While a probe of related structure has previously been used
to report on levels of MAO,27 the potential contribution of MAO
to oLOX activation in human lung tissue was negated by the fact
that clorgyline (a MAO-A inhibitor) and pargyline (a MAO-BChem. Sci. This journal is © The Royal Society of Chemistry 2015
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View Article Onlineinhibitor) did not cause any signicant reduction in uorescent
signal (Fig. 3). Furthermore, BAPN does not inhibit MAO,54 thus
conrming that MAO does not cleave 1 in this model.Optical molecular imaging of LOX
Whilst uorometric determination of LOX in human tissue has
been demonstrated (Fig. 2), the pivotal advance would be the
dynamic imaging of LOX activity in tissue in situ without the
need for homogenisation. This heralds the capability to
perform optical molecular ‘biopsies’ in situ with optical
molecular imaging techniques.55,56 Fibred confocal uorescence
microscopy (FCFM) allows a exible optical bre bundle to be
passed down the working channel of an endoscope while uti-
lising laser excitation at 488 nm. FCFM has been successfully
utilised in a number of organ systems including the pulmonary
tract,57,58 where the autouorescence of the elastin allows visu-
alisation of tissue architecture. This approach allows the real-
time in vivo visualisation of tissue at a cellular level and is a
clinically applicable strategy.Fig. 4 oLOX can be used alongside ﬁbred confocal ﬂuorescence micros
biopsies. (a) Architecture of the FCFM (Cellvizio®-Lung System (Mauna K
confocal microscopy (b) the tip of the ﬁbre optic is superimposed on a ﬁx
of the ﬁbre (1.4 mm). (c) Representative single frame images generated
bation with 10 mM oLOX. The graph (d) represents the mean auto-ﬂuore
ﬂuorescence (n ¼ 4). Note the signiﬁcant reduction in ﬂuorescence on in
signed rank test).
This journal is © The Royal Society of Chemistry 2015Hence we evaluated oLOX 1 in conjunction with FCFM, as an
optical molecular imaging strategy by applying oLOX to aged
human lung tissue ex vivo. To demonstrate that the resultant
increase in uorescence detected by FCFM could be inhibited
and prove the specicity of oLOX, we also incubated human
lung tissue with BAPN (Fig. 4).
Moving from sections of tissue (Fig. 4) to whole organ
imaging was the next challenge. Hence, in order to assess the
utility of oLOX 1 in situ, a ventilating ex vivo asinine lung model
was used (Fig. 5 and ESI Fig. S3–4†). We have recently reported
that aged donkeys suﬀer from a high prevalence of pulmonary
brosis (35%) (oen resulting in euthanasia), which has been
likened to a brotic interstitial lung disease of humans.59 A
whole, ex vivo, donkey lung was thus used to assess the utility of
combining FCFM with the local intrapulmonary delivery of
oLOX. Utilising this size relevant and spontaneous model
negated the need for an experimental model under the 3Rs
(Replacement, Reduction and Renement) ethos. A signicant
increase in uorescent signal over background was detectedcopy (FCFM) to demonstrate oLOX activity in ex vivo human lung tissue
ea Technologies, Paris, France))† involving a ﬁbre bundle and scanning
ed lung tissue section with the white bar corresponding to the diameter
by FCFM on fresh sections of aged human lung tissue following incu-
scence of each 60 sec video imaging period adjusted for tissue auto-
cubation with the lysyl oxidase inhibitor, BAPN (*p ¼ 0.0286, Wilcoxon
Chem. Sci.
Fig. 5 oLOX can be used to image LOXF activity in a ﬁbrotic ventilating ex vivo asinine lung model. Catheter installation of 200 mM oLOX instilled
in a total volume of 1mL in PBS into a whole ﬁbrotic ventilating ex vivo asinine lung results in a signiﬁcant increase in ﬂuorescent signal (a and b, *p
¼ 0.0313, Wilcoxon signed rank test, n ¼ 3); (c) tissue shown in (a) was excised and evaluated for LOX expression using immunohistochemistry
(20 lens). (d) Western blot conﬁrmed expression of LOX in both ﬁbrotic and grossly unaﬀected (control) areas of ex vivo asinine lung tissue.
Chemical Science Edge Article
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View Article Onlinefollowing the installation of oLOX 1 into brotic regions of
whole ventilating ex vivo asinine lung that were subsequently
conrmed to express LOX (Fig. 5c). The coupling of oLOX 1 with
FCFM enables the minimally invasive visualisation of temporal
and spatial alterations in the molecular activity of LOXF.Conclusions
We have successfully designed and synthesized an activity-
based uorescent probe capable of the real-time quantication
of LOXF activity in brogenic conditions. The activation of the
probe by LOXF was conrmed in human lung homogenate
models. Furthermore, probe activation was inhibited in the
presence of a specic LOX inhibitor, thus conrming target
specicity. The probe also showed utility in a size-relevant
model of lung brogenesis. This optical Smartprobe has the
potential to image real-time LOXF activity within the lungs of
patients. Signicant signal amplication is detected aer 30
min, a time-point that is feasible for bedside imaging. Whilst we
have not yet assessed the specicity of oLOX to individual
members of the LOXF family, targeting individual enzymes is a
future goal, exploiting the use of specic inhibitor basedChem. Sci.imaging agents. A further goal is to develop oLOX sensors that
permit more rapid uorescent amplication.Acknowledgements
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